Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02819895
Other study ID # 15-012572
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 2016
Est. completion date June 30, 2018

Study information

Verified date July 2018
Source Children's Hospital of Philadelphia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if in a rural setting of Ondo State, Nigeria, a customized automated telephone and email immunization reminder system will be feasible, acceptable, and significantly improve immunization utilization rates.


Description:

Background: Worldwide, vaccine preventable diseases account for 29% of all deaths between 1 month and 5 years, underscoring the importance of immunizations. In Nigeria, routine childhood immunization rates are unacceptably inconsistent and low, ranging from 35-85% at 14 weeks and 10-37% for all routine immunizations at 12-24 months.

GAP: The feasibility, acceptability and utility of an automated phone immunization reminder system have never been explored in this rural setting of Nigeria.

HYPOTHESIS: Given ~90% of the adult population in Nigeria uses a mobile phone, a customized mHealth immunization reminder system will be feasible and acceptable; and will significantly improve immunization rates in this rural setting of Ondo State, Nigeria.

METHODS: A prospective randomized controlled trial study design will be utilized. This study will recruit parents of healthy newborn infants delivered at Mother and Child Hospital Ondo, who live in Akure or Ondo Town and plan to receive their immunizations at Mother and Child Hospital Ondo.

DATA ANALYSIS: The proportion of immunization visits between intervention and control groups will be compared using a two-sided, two sample test of proportions with p <0.05 being significant. Secondary analysis will focus on the predictive value of social demographic variables on immunization rates.


Recruitment information / eligibility

Status Completed
Enrollment 600
Est. completion date June 30, 2018
Est. primary completion date July 31, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 1 Week
Eligibility Inclusion Criteria:

1. Parents of healthy infants who have a cellular phone

2. Born at Mother and Child Hospital Ondo (Akure or Ondo Town)

3. Plans to receive immunizations at Mother and Child Hospital Ondo

Exclusion Criteria:

1. Parents of infants requiring hospital admission due to illness or prematurity.

2. Parents without a cellular phone

Study Design


Related Conditions & MeSH terms


Intervention

Other:
A customized windows® software application
A customized windows® software application with the ability to send automated voice call, SMS and email reminder about due dates for childhood routine immunizations.

Locations

Country Name City State
Nigeria Mother and Child Hospital Ondo Akure Ondo State
Nigeria Mother and Child Hospital Ondo Ondo

Sponsors (2)

Lead Sponsor Collaborator
Children's Hospital of Philadelphia Thrasher Research Fund

Country where clinical trial is conducted

Nigeria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immunization Rates at 14 weeks To determine if an automated customized telephone and email immunization reminder system can increase the 14-week immunization rates, by at least 10% among those who receive immunization reminders versus those who do not. 14 Weeks
Secondary Immunization Rates at 14 Months To determine the effect of an automated customized phone and email immunization reminder system on the proportion of children completely immunized at 14 months among those who receive immunization reminders versus those who do not. 14 Months
Secondary Timeliness of Immunization Receipt To determine if the proportion of infants who receive their immunizations within 1-week of its due date is higher in infants of parents who receive phone and email immunization reminders versus those who do not. 14 Months
See also
  Status Clinical Trial Phase
Completed NCT02526394 - Pertussis and Meningitis C Concomitant Vaccination in Adolescents Phase 4
Completed NCT01707212 - Prenatal Education About Infant Immunization Pain Management Phase 3
Completed NCT01463176 - Music Therapy as Procedural Support for Young Children Undergoing Immunizations N/A
Completed NCT01193335 - Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants. Phase 4
Completed NCT04222595 - FluPRINT Study: Characterisation of the Immune and Transcriptional Response to LAIV N/A
Completed NCT05794113 - Comparing the Use of a Mobile App for Surveillance of Adverse Events Following Influenza Immunization to a Web-Based Platform N/A
Recruiting NCT01713322 - Testing Educational Materials in a Paediatric Setting Phase 3
Not yet recruiting NCT03705455 - Immunization Schedule Alert Platform N/A
Recruiting NCT01601197 - A Study of Two Injection Techniques to Reduce Pain in Infants Undergoing Immunization Phase 3
Completed NCT01296906 - Population Versus Practice-based Interventions to Increase Immunizations N/A
Completed NCT01399814 - Restricted Intravenous Fluid Regime Effects on Immunological Indicators of Elderly Patients Operated for Abdominal Cancer Phase 3
Completed NCT01390363 - Study of Adolescent Immunization Recall Systems N/A
Completed NCT02609035 - Immunization Services Model for Adult Rate Improvement N/A
Recruiting NCT02200276 - Influenza Immunization in Adults Over Age 75 N/A
Completed NCT01677702 - Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization N/A
Recruiting NCT05213000 - Adjuvant Effect of Physical Exercise on Immune Response to COVID-19 Vaccination and Interactions With Stress N/A
Completed NCT03188692 - Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants Phase 3
Completed NCT02432430 - Comparison of Immunization Quality Improvement Dissemination Study N/A
Completed NCT01379846 - Study of TAK-816 in Healthy Infants Phase 3
Active, not recruiting NCT03943875 - GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose Phase 4